Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD

Generally, inflammatory bowel disease (IBD) can be caused by psychology, genes, environment, and gut microbiota. Therefore, IBD therapy should be improved to utilize multiple strategies. Shen Ling Bai Zhu San (SLBZS) adheres to the aim of combating complex diseases from an integrative and holistic p...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2019-01, Vol.2019 (2019), p.1-30
Main Authors: Guo, Shining, Xu, Xiaolong, Xiong, Ying, Li, Yue, Li, Zeng-quan, Chen, Wen-qian, Li, Yue-fei, Liu, Cui, Lv, Weijie, Chao, Limin
Format: Article
Language:English
Subjects:
Acids
B cells
Bioavailability
Bioinformatics
Drugs, Chinese Herbal - pharmacology
Drugs, Chinese Herbal - therapeutic use
Gastrointestinal diseases
Herbal medicine
Humans
Inflammatory bowel disease
Inflammatory Bowel Diseases - drug therapy
Irritable bowel syndrome
Medicine
Microbiota
Microbiota (Symbiotic organisms)
Permeability
Pharmacology
Physiological aspects
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Generally, inflammatory bowel disease (IBD) can be caused by psychology, genes, environment, and gut microbiota. Therefore, IBD therapy should be improved to utilize multiple strategies. Shen Ling Bai Zhu San (SLBZS) adheres to the aim of combating complex diseases from an integrative and holistic perspective, which is effective for IBD therapy. Herein, a systems pharmacology and microbiota approach was developed for these molecular mechanisms exemplified by SLBZS. First, by systematic absorption-distribution-metabolism-excretion (ADME) analysis, potential active compounds and their corresponding direct targets were retrieved. Then, the network relationships among the active compounds, targets, and disease were built to deduce the pharmacological actions of the drug. Finally, an “IBD pathway” consisting of several regulatory modules was proposed to dissect the therapeutic effects of SLBZS. In addition, the effects of SLBZS on gut microbiota were evaluated through analysis of the V3-V4 region and multivariate statistical methods. SLBZS significantly shifted the gut microbiota structure in a rat model. Taken together, we found that SLBZS has multidimensionality in the regulation of IBD-related physiological processes, which provides new sights into herbal medicine for the treatment of IBD.
ISSN:1942-0900
1942-0994
DOI:10.1155/2019/8194804